Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Zymeworks Inc ZYME

Zymeworks Inc. is a global biotechnology company. The Company is engaged in the discovery, development, and commercialization of multifunctional biotherapeutics to treat cancer and other serious diseases. Its complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop differentiated antibody-based therapeutic candidates. Its platforms include Azymetric, Drug Conjugate Platforms, EFECT, and ProTECT. Its lead product candidate, zanidatamab, is a bispecific antibody that targets two distinct domains of the human epidermal growth factor receptor 2 (HER2). Its second product candidate, zanidatamab zovodotin, combines the biparatopic antibody design of zanidatamab with its ZymeLink auristatin antibody-drug conjugate (ADC) technology, comprised of its cytotoxin (cancer cell-killing compound) and cleavable linker. Its pipeline includes four preclinical candidates: ZW191, ZW171, ZW220, and ZW251.


NDAQ:ZYME - Post by User

Comment by ghayeson Nov 10, 2021 3:29am
134 Views
Post# 34108345

RE:Slides to today’s conference…

RE:Slides to today’s conference…
Gringotts wrote:

Link to the presentation slides used at today's conference  

https://ir.zymeworks.com/static-files/ec2ab511-256d-44c4-9b5e-aba93f3ec09c
 

Major take away:
BLOCKBUSTER peak sales potential for ZYME's line of cancer treatments. 


So  their product is Zanidatamab for GastroIntestinal Cancer,  the clinical trials look good. Now they are setting up a full scale trial in 300 sites over 38 countries - looking for approval within 2, 3, 5 years if the study verifies the clinical trial results. - Could be a blockbuster., possibly one of the pharmacutical giants might buy it up as soon as they see the study is launched? Anyhow - thanks for the slices - seems to be a mass of potential here. 
<< Previous
Bullboard Posts
Next >>